Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Highlights Gram Scale Protein Production Capability using CHO Transient Transfection in an Upcoming Educational Webinar Presentation
March 20, 2012
Tom Boone, Protein Engineering Expert and Former VP of Amgen Protein Sciences, to Deliver the Introduction for a Breakthrough Antibody Production Application
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is hosting an educational webinar entitled "Producing Gram Scale Quantities of Antibodies and Proteins Using MaxCyte® Transient Transfection" on Thursday, March 22, 2012, from 11:00 AM - 12:00 PM EDT. Tom Boone, former Vice President of Amgen Protein Sciences and a leading expert in protein engineering and production, will provide key insights during this scientific program. The discussion will focus on demonstrating how screening and bioproduction programs can be streamlined cost-effectively from months to weeks using transient transfection
This webinar will highlight an innovative application of MaxCyte's proprietary flow electroporation which has led to the breakthrough ability to produce gram scale quantities of proteins within weeks of initiating expression projects. "Researchers are no longer tied to construction of a stable cell line for each new protein or antibody that they want to express," says Douglas Doerfler, President, and CEO of MaxCyte. "A critical aspect of this capability is its compatibility with CHO cells, eliminating the need to begin protein expression efforts in HEK cells or other irrelevant cell lines." Data within the webinar will demonstrate how biotherapeutic development pipelines can be shortened by months when working directly in CHO cells, providing a compelling alternative to the reliance on stable cell lines for larger scale protein production.
"The biopharmaceutical industry has expressed tremendous interest in using MaxCyte's transient transfection platforms for protein production and biotherapeutic development," says Dr. Karen Donato, EVP of Global Business Development and Marketing at MaxCyte. "The capabilities of the MaxCyte technology meet a long unfulfilled need to rapidly produce proteins and antibodies in relevant cells from the earliest stages of development." MaxCyte offers two systems, the MaxCyte STX and the MaxCyte VLX, which are capable of large scale transient transfection in a single 20-30 minute run to produce gram level quantities of antibodies and proteins.
Interested participants can register for the webinar on MaxCyte's web site, www.maxcyte.com, to learn how MaxCyte Scalable Transfection Systems can accelerate biotherapeutic development pipelines using large scale, transient transfection of CHO and other relevant cells.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed a portfolio of products including the MaxCyte® STX™ Scalable Transfection System and MaxCyte® VLX™ Large Scale Transfection System, ideal tools for use in drug discovery research, screening, and protein production environments. These products enable the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell-?based assays, with comparable results and Seamless Scalability™ from the bench to HTS and pilot scale.